Impact of non-selective beta blockers on portal hypertension and hepatic elasticity in hepatitis C virus-related liver cirrhosis

Aim. To establish the diagnostic accuracy of liver and spleen density (LD and SD) measurements in patients with compensated alcoholic liver cirrhosis (LC) in the diagnosis of portal hypertension. Subjects and methods. The investigation enrolled 83 patients with compensated alcoholic and viral (hepatitis C virus) LC. All the patients underwent LD and SD determinations, abdominal ultrasonography, and endoscopy to detect esophageal varices (EV), as well as examination of blood indices. Results. In viral LC, there were substantial LD differences in patients with and without EV. The patients with EV were ascertained to have higher LD [27.9 (21—45) kPa] than those without EV [19.5 (16—26.2) kPa]. SD was also significantly higher than that in the EV group than in the non-EV group (p

Download Full-text

Hemodynamic effects of direct-acting antivirals in patients with hepatitis-C virus-associated cirrhosis and portal hypertension non responsive to beta-blockers

Journal of Hepatology ◽

10.1016/s0168-8278(20)31874-2 ◽

2020 ◽

Vol 73 ◽

pp. S705-S706

Author(s):

Edilmar Alvarado ◽

Sabela Lens ◽

Alba Ardevol ◽

Marta García Guix ◽

Anna Baiges ◽

...

Keyword(s):

Hepatitis C Virus ◽

Portal Hypertension ◽

Hepatitis C ◽

Beta Blockers ◽

Direct Acting Antivirals ◽

Hemodynamic Effects ◽

Direct Acting

Download Full-text

Avoiding Beta Blockers in Patients of Hepatitis C Virus-Related Compensated Cirrhosis With Clinically Significant Portal Hypertension After Cure With Antivirals

The American Journal of Gastroenterology ◽

10.14309/ajg.0000000000001267 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Sanchit Sharma ◽

Anoop Saraya

Keyword(s):

Hepatitis C Virus ◽

Portal Hypertension ◽

Hepatitis C ◽

Beta Blockers ◽

Compensated Cirrhosis ◽

Clinically Significant

Download Full-text

The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus

Terapevticheskii arkhiv ◽

10.26442/00403660.2020.02.000511 ◽

2020 ◽

Vol 92 (2) ◽

pp. 34-42

Author(s):

E. A. Nabatchikova ◽

D. T. Abdurakhmanov ◽

E. N. Nikulkina ◽

T. P. Rozina ◽

E. L. Tanaschuk ◽

...

Keyword(s):

Risk Factors ◽

Liver Cirrhosis ◽

Hepatitis C Virus ◽

Portal Hypertension ◽

Hepatitis C ◽

Liver Function ◽

Total Bilirubin Level ◽

Virologic Response ◽

Direct Acting Antiviral ◽

Class B

Aim.To study liver function and portal hypertension, incidence and risk factors of liver-related complications, including hepatocellular carcinoma (HCC), in patients with HCV-related liver cirrhosis achieved sustained virologic response (SVR) after direct-acting antiviral therapy. Materials and methods.Patients with HCV-related liver cirrhosis were followed up after achievement SVR with assessment of liver function parameters, portal hypertension, Model for End-stage Liver Disease (MELD) and Сhild Pugh (CP) scores, complications development, including HCC, every 36 months. The median follow-up duration was 24 [18; 30] months after end of treatment. Results.At last observation, a number of cirrhotic patients with CP class A increased from 72% to 85%, with CP class B reduced from 23.5% to 12.5%, with CP class C from 4.5% to 2.5%. In 89% patients were identified a regress of liver fibrosis (from 23.5 [16.9; 28] to 15.0 [10.2; 21.3] kPa,p0.005), each third patient reduction of fibrosis stage to F2/F3. In 19 (9.5%) patients were occurred liver-related complications, including HCC (in 9 patients). Baseline high total bilirubin level (34 mol/l) (Hazard ratio (HR) 11.5, 95% confidence interval (CI) 2.357.8,р0.005) and ascites (HR=17.6, 95% CI 2.1144.8,p=0.008) were independent risk factors associated with HCC development. Conclusion.The risk of HCC development remains in patients with HCV-related liver cirrhosis, despite on eradication of hepatitis C virus. Therefore, these patients should continue to undergo more intensive examination (ultrasound examination and determination of alfa-fetoprotein level each 36 months), including contrast-enhanced methods of imaging, the frequency of which should be determined.

Download Full-text

Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study

Pathogens and Disease ◽

10.1093/femspd/ftab008 ◽

2021 ◽

Author(s):

Haidi Karam-Allah Ramadan ◽

Gamal Badr ◽

Nancy K Ramadan ◽

Aml Sayed

Keyword(s):

Immune Response ◽

Liver Cirrhosis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Immune Responses ◽

Signaling Pathways ◽

Liver Diseases ◽

Stat Signaling ◽

Chronic Hcv ◽

Direct Acting

Abstract The use of direct-acting antivirals (DAAs) therapy for the treatment of hepatitis C virus (HCV) results in a high sustained virological response (SVR) and subsequently alters liver immunologic environment. However, hepatocellular carcinoma (HCC) may occur after DAAs treatment. We aimed to clarify changes of immune responses, PI3K/AKT and JAK/STAT signaling pathways in HCV-induced liver diseases and HCC following DAAs treatment. Four cohorts are classified as chronic HCV patients, HCV-related cirrhosis without HCC, HCV-related cirrhosis and HCC, and healthy control group. The patient groups were further divided into treated or untreated with DAAs with SVR12. Increased percentages of CD3, CD8 and CD4, decreased CD4/FoxP3/CD25, CD8/PD-1 and CD19/PDL-1 were found in DAAs-treated patients in the three HCV groups. Following DAAs therapy, the levels of ROS, IL-1β, IL-6, IL-8 and TNF-α were significantly decreased in the three HCV groups. Treated HCV patients showed up regulation of p-AKT and p-STAT5 and down regulation of p-STAT3, HIF-1α and COX-2. In conclusion, DAAs enhance the immune response in chronic HCV and liver cirrhosis, hence our study is the first to show change in PI3K/AKT and JAK/STAT signaling pathways in different HCV-induced liver diseases after DAAs. In chronic HCV, DAAs have better impact on the immune response while in liver cirrhosis not all immune changes were prominent.

Download Full-text